Medscape is available in 5 Language Editions – Choose your Edition here.


Gonadoblastoma Treatment & Management

  • Author: Joseph L Lasky, III, MD; Chief Editor: Max J Coppes, MD, PhD, MBA  more...
Updated: Jun 05, 2014

Medical Care

After the DSD or other high-risk condition is characterized, the treatment of gonadoblastoma is surgical. Thereafter, patients must be observed by an endocrinologist, who supplements any deficiencies in gonadal or adrenal function.


Surgical Care

See the list below:

  • In patients with mixed gonadal dysgenesis, perform bilateral gonadectomy soon after establishing the diagnosis.
    • In a review of 140 patients with dysgenic gonads, Troche and Hernandez (1986) found that the neoplastic transformation of abnormal gonads was common, and bilateral involvement occurred in 38.6% of patients.[12]
    • Patients with mixed gonadal dysgenesis (45,X/46,XY) have an incidence of developing gonadoblastoma of 30-66%. Therefore, most authorities recommended performing bilateral gonadectomy as soon as the diagnosis of gonadal dysgenesis is made.
  • In patients with complete androgen insensitivity and male pseudohermaphroditism (46,XY) with normal phenotypic genitalia, Rutgers and Scully (1991) recommended that gonadectomy be performed after puberty but before the individual is aged 20 years.[20]
    • This opinion is based on the negligible risk of finding gonadoblastoma in these patients before puberty. However, the overall risk of developing a seminoma/dysgerminoma is 9%; therefore, perform gonadectomy before the individual is aged 20 years.
    • In patients with partial androgen insensitivity and male pseudohermaphrodism (46,XY), the phenotypes are frequently unpredictable, and gonadectomy is recommended early in conjunction with any other procedure that may be required.
    • Additionally, 2 other reasons explain why patients with the complete form of androgen insensitivity should have gonadectomy performed after puberty. The reasons are as follows:
      • First, these patients usually receive the diagnosis after puberty when they present with primary amenorrhea.
      • Second, intra-abdominal testicular tissue allows for normal breast development, which allows these phenotypic (46,XY) girls to go through "normal" puberty. This mechanism is initiated when the pituitary release of gonadotropic hormones stimulates the production of testosterone by the testes. Being completely androgen insensitive, the ability to recognize the elevated testosterone concentration does not exist, and the biofeedback mechanism fails to function appropriately, resulting in constant elevated levels of serum LH and testosterone. In the peripheral adipose tissues, testosterone is converted by aromatase to 17-beta-estradiol. The high levels of 17-beta-estradiol allow for normal breast development and the overall feminization of the individual.
  • Patients with Turner syndrome have been reported to have anywhere from 6-9% incidence of XY mosaicism. Debate remains as to whether screening all patients with Turner syndrome stigmata for the presence of Y chromosome mosaicism is worthwhile. No consensus has been reached regarding the necessity of performing prophylactic gonadectomies on all patients with Turner syndrome. However, in the presence of virilizing symptoms in a patient with Turner syndrome, looking for a Y chromosome is probably indicated. If found, these patients should undergo prophylactic gonadectomy, as the incidence of gonadoblastoma development in these patients has been reported to be as high as 43%.
  • Individualize the surgical approach to gonadectomy based on the patient's particular anatomy.
    • After clearly defining the DSD, a transscrotal/translabial, inguinal, or transabdominal approach can be used to perform the gonadectomy.
    • If the DSD or the patient's anatomy has not been established clearly, a transabdominal exploration can help to delineate the unpredictable anatomic variability of each individual.


See the list below:

  • Obtain a consultation with a pediatric urologist when any suspicion of an intersex disorder is noted. Often the neonatal anatomy is difficult to diagnose with imaging studies alone, and cystoscopy and vaginoscopy may need to be performed.
  • A consultation with a clinical geneticist can also be useful in patients who do not have a clearly defined genotype.
  • Obtain an endocrinology evaluation to manage life-long hormone replacement needs.
  • Patients with complete androgen insensitivity and male pseudohermaphroditism (46,XY) who receive the diagnosis late (eg, after puberty) should have a consultation with a surgeon for removal of the abnormal gonadal tissue.
  • Although not directly pertaining to gonadoblastoma, an ethics consultation is often needed to help define the best treatment plan for children with intersex disorders.


After surgery, start a clear liquid diet as soon as the patient regains normal bowel function and appropriately advance the diet.



Patients are out of bed on postoperative day 1 and resume full normal activity 4 weeks after surgery.

Contributor Information and Disclosures

Joseph L Lasky, III, MD Clinical Associate Professor of Pediatrics and Neurosurgery, University of California, Los Angeles, David Geffen School of Medicine; Chief, Division of Pediatric Hematology/Oncology, Harbor-UCLA Medical Center

Joseph L Lasky, III, MD is a member of the following medical societies: American Association for Cancer Research, American Society of Pediatric Hematology/Oncology, Children's Oncology Group, Society for Neuro-Oncology, American Society of Clinical Oncology

Disclosure: Received grant/research funds from Novo-Nordisk for site pi; Received grant/research funds from Emmaus for site pi; Received consulting fee from Octapharma for consulting; Received consulting fee from CSL Behring for consulting; Received grant/research funds from Novartis for site pi.


Kathleen M Sakamoto, MD, PhD Shelagh Galligan Professor, Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine

Kathleen M Sakamoto, MD, PhD is a member of the following medical societies: International Society for Experimental Hematology, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Society for Pediatric Research

Disclosure: Nothing to disclose.

Nejd F Alsikafi, MD Clinical Assistant Professor, Department of Urology, Loyola University, Chicago Stritch School of Medicine

Nejd F Alsikafi, MD is a member of the following medical societies: American Urological Association, Endourological Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Timothy P Cripe, MD, PhD, FAAP Chief, Division of Hematology/Oncology/BMT, Gordon Teter Endowed Chair in Pediatric Cancer, Nationwide Children's Hospital; Professor of Pediatrics, Ohio State University College of Medicine

Timothy P Cripe, MD, PhD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American Association for Cancer Research, American Pediatric Society, American Society of Gene and Cell Therapy, American Society of Pediatric Hematology/Oncology, Connective Tissue Oncology Society, Society for Pediatric Research, Children's Oncology Group

Disclosure: Nothing to disclose.

Chief Editor

Max J Coppes, MD, PhD, MBA Executive Vice President, Chief Medical and Academic Officer, Renown Heath

Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American College of Healthcare Executives, American Society of Pediatric Hematology/Oncology, Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Stephan A Grupp, MD, PhD Director, Stem Cell Biology Program, Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia; Associate Professor of Pediatrics, University of Pennsylvania School of Medicine

Stephan A Grupp, MD, PhD is a member of the following medical societies: American Association for Cancer Research, Society for Pediatric Research, American Society for Blood and Marrow Transplantation, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.


William J Cromie, MD, MBA President and Chief Executive Officer, Health Care, Capital District Physicians' Health Plan

William J Cromie, MD, MBA is a member of the following medical societies: American Academy of Pediatrics, American College of Surgeons, American Medical Association, American Urological Association, Medical Society of the State of New York, Société Internationale d'Urologie (International Society of Urology), Society for Pediatric Urology, Society of University Urologists, and Society of Uroradiology

Disclosure: Nothing to disclose.

Dimitri Kuznetsov, MD Staff Physician, Department of Surgery, Section of Urology, University of Chicago

Dimitri Kuznetsov, MD is a member of the following medical societies: American Urological Association and Endourological Society

Disclosure: Nothing to disclose.

  1. Scully RE. Gonadoblastoma. A review of 74 cases. Cancer. 1970 Jun. 25(6):1340-56. [Medline].

  2. SCULLY RE. Gonadoblastoma; a gonadal tumor related to the dysgerminoma (seminoma) and capable of sex-hormone production. Cancer. 1953 May. 6(3):455-63. [Medline].

  3. Page DC. Hypothesis: a Y-chromosomal gene causes gonadoblastoma in dysgenetic gonads. Development. 1987. 101 Suppl:151-5. [Medline].

  4. Tsuchiya K, Reijo R, Page DC, Disteche CM. Gonadoblastoma: molecular definition of the susceptibility region on the Y chromosome. Am J Hum Genet. 1995. 57(6):1400-7. [Medline].

  5. Li Y, Lau YF. TSPY and its X-encoded homologue interact with cyclin B but exert contrasting functions on cyclin-dependent kinase 1 activities. Oncogene. 2008 Jun 30. [Medline].

  6. Kido T, Lau YF. The human Y-encoded testis-specific protein interacts functionally with eukaryotic translation elongation factor eEF1A, a putative oncoprotein. Int J Cancer. 2008 Oct 1. 123(7):1573-85. [Medline].

  7. Lau YF, Li Y, Kido T. Gonadoblastoma locus and the TSPY gene on the human Y chromosome. Birth Defects Res C Embryo Today. 2009 Mar. 87(1):114-22. [Medline].

  8. Kido T, Lau YF. A Cre gene directed by a human TSPY promoter is specific for germ cells and neurons. Genesis. 2005 Aug. 42(4):263-75. [Medline].

  9. Brant WO, Rajimwale A, Lovell MA, et al. Gonadoblastoma and Turner syndrome. J Urol. 2006 May. 175(5):1858-60. [Medline].

  10. Scully RE. Ovarian tumors. A review. Am J Pathol. 1977 Jun. 87(3):686-720. [Medline].

  11. Gravholt CH, Fedder J, Naeraa RW, Muller J. Occurrence of gonadoblastoma in females with Turner syndrome and Y chromosome material: a population study. J Clin Endocrinol Metab. 2000 Sep. 85(9):3199-202. [Medline]. [Full Text].

  12. Troche V, Hernandez E. Neoplasia arising in dysgenetic gonads. Obstet Gynecol Surv. 1986 Feb. 41(2):74-9. [Medline].

  13. Michala L, Goswami D, Creighton SM, Conway GS. Swyer syndrome: presentation and outcomes. BJOG. 2008 May. 115(6):737-41. [Medline].

  14. Subbiah V, Huff V, Wolff JE, Ketonen L, Lang FF Jr, Stewart J, et al. Bilateral gonadoblastoma with dysgerminoma and pilocytic astrocytoma with WT1 GT-IVS9 mutation: A 46 XY phenotypic female with Frasier syndrome. Pediatr Blood Cancer. 2009 Dec 15. 53(7):1349-51. [Medline].

  15. Patel PR, Pappas J, Arva NC, Franklin B, Brar PC. Early presentation of bilateral gonadoblastomas in a Denys-Drash syndrome patient: a cautionary tale for prophylactic gonadectomy. J Pediatr Endocrinol Metab. 2013. 26(9-10):971-4. [Medline].

  16. Quinonez SC, Park JM, Rabah R, Owens KM, Yashar BM, Glover TW. 9p partial monosomy and disorders of sex development: review and postulation of a pathogenetic mechanism. Am J Med Genet A. 2013 Aug. 161A(8):1882-96. [Medline].

  17. Esin S, Baser E, Kucukozkan T, Magden HA. Ovarian gonadoblastoma with dysgerminoma in a 15-year-old girl with 46, XX karyotype: case report and review of the literature. Arch Gynecol Obstet. 2012 Feb. 285(2):447-51. [Medline].

  18. Verp MS, Simpson JL. Abnormal sexual differentiation and neoplasia. Cancer Genet Cytogenet. 1987 Apr. 25(2):191-218. [Medline].

  19. Hersmus R, Stoop H, White SJ, Drop SL, Oosterhuis JW, Incrocci L. Delayed Recognition of Disorders of Sex Development (DSD): A Missed Opportunity for Early Diagnosis of Malignant Germ Cell Tumors. Int J Endocrinol. 2012. 2012:671209. [Medline].

  20. Rutgers JL, Scully RE. The androgen insensitivity syndrome (testicular feminization): a clinicopathologic study of 43 cases. Int J Gynecol Pathol. 1991. 10(2):126-44. [Medline].

  21. Chen MJ, Yang JH, Mao TL, et al. Successful pregnancy in a gonadectomized woman with 46,XY gonadal dysgenesis and gonadoblastoma. Fertil Steril. 2005 Jul. 84(1):217. [Medline].

  22. Frias JL, Davenport ML. Health supervision for children with Turner syndrome. Pediatrics. 2003 Mar. 111(3):692-702. [Medline].

  23. Gourlay WA, Johnson HW, Pantzar JT, et al. Gonadal tumors in disorders of sexual differentiation. Urology. 1994 Apr. 43(4):537-40. [Medline].

  24. Lau YF. Gonadoblastoma, testicular and prostate cancers, and the TSPY gene. Am J Hum Genet. 1999 Apr. 64(4):921-7. [Medline].

  25. Levin HS. Tumors of the testis in intersex syndromes. Urol Clin North Am. 2000 Aug. 27(3):543-51, x. [Medline].

  26. Mendes JR, Strufaldi MW, Delcelo R, et al. Y-chromosome identification by PCR and gonadal histopathology in Turner's syndrome without overt Y-mosaicism. Clin Endocrinol (Oxf). 1999 Jan. 50(1):19-26. [Medline].

  27. Pena-Alonso R, Nieto K, Alvarez R, et al. Distribution of Y-chromosome-bearing cells in gonadoblastoma and dysgenetic testis in 45,X/46,XY infants. Mod Pathol. 2005 Mar. 18(3):439-45. [Medline].

  28. Rutgers JL, Scully RE. Pathology of the testis in intersex syndromes. Semin Diagn Pathol. 1987 Nov. 4(4):275-91. [Medline].

  29. Sultana R, Myerson D, Disteche CM. In situ hybridization analysis of the Y chromosome in gonadoblastoma. Genes Chromosomes Cancer. 1995 Aug. 13(4):257-62. [Medline].

  30. Tewari K, Cappuccini F, Disaia PJ, et al. Malignant germ cell tumors of the ovary. Obstet Gynecol. 2000 Jan. 95(1):128-33. [Medline].

  31. Vlasak I, Plochl E, Kronberger G, et al. Screening of patients with Turner syndrome for "hidden" Y-mosaicism. Klin Padiatr. 1999 Jan-Feb. 211(1):30-4. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.